BNP Paribas Financial Markets
LVTX

BNP Paribas Financial Markets’s LAVA Therapeutics LVTX Stock Holding History

BNP Paribas Financial Markets’s Portfolio LVTX Stock Details LVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-46,900
Closed -$61.9K – 5688
2025
Q2 		$61.9K Buy
46,900
+1,600
+4% +$2.04K ﹤0.01% 4173
2025
Q1 		$57.5K Buy
45,300
+3,500
+8% +$3.9K ﹤0.01% 4242
2024
Q4 		$39.8K Buy
+41,800
New +$65.6K ﹤0.01% 4517

Other funds holding LVTX

SC
Shay Capital New York $1.2B AUM 37.4% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $526M AUM 175.27% 1-Year Est. Return
GS
GTS Securities New York $2.83B AUM 21.76% 1-Year Est. Return
RC
Rangeley Capital New Canaan, Connecticut $103M AUM 77.36% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

BNP Paribas Financial Markets's LVTX Position: Q3 2025 in Review

BNP Paribas Financial Markets sold out of LAVA Therapeutics (LVTX) in Q3 2025, closing a stake of 46,900 shares — an estimated $61.9K sold.

BNP Paribas Financial Markets first reported a position in LVTX in Q4 2024 and held it in 3 quarters. The position peaked at $61.9K in Q2 2025. 21 funds tracked by Wall St. Rank hold LVTX as of Q3 2025.

  • BNP Paribas Financial Markets reported no remaining LAVA Therapeutics position as of Q3 2025 after selling out during the quarter.
  • BNP Paribas Financial Markets sold 46,900 LAVA Therapeutics shares in Q3 2025, an estimated $61.9K.
  • BNP Paribas Financial Markets first reported a position in LAVA Therapeutics in Q4 2024 and held it in 3 quarters.
  • BNP Paribas Financial Markets's LAVA Therapeutics position peaked at $61.9K in Q2 2025.
  • 21 funds tracked by Wall St. Rank held LAVA Therapeutics as of Q3 2025.

Based on BNP Paribas Financial Markets's 13F filing for Q3 2025, filed 13 Nov 2025.